Biologics & Regenerative Medicine
Biologics in orthopedic surgery are tissue-derived and cell-based products — including amniotic tissue allografts, platelet-rich plasma (PRP), bone morphogenetic proteins (BMPs), and demineralized bone matrix (DBM) — used to promote healing, reduce inflammation, and augment fusion in musculoskeletal procedures. The orthopedic biologics market is projected to exceed $10 billion by 2027, driven by growing clinical evidence for regenerative applications in sports medicine, spine fusion, and wound healing. This hub covers the clinical options, evidence base, and practical considerations for surgical teams evaluating biologics.
Biologics Guides
-
OVERVIEW
What Are Biologics in Orthopedic Surgery? A Complete Overview
The full biologics product landscape — bone grafts, growth factors, amniotic tissue, PRP, and stem cell products — how each works mechanistically, where they’re used clinically, and what the current evidence supports.
-
CLINICAL APPLICATION
Amniotic Tissue in Surgery: Applications, Benefits, and Evidence
How amniotic membrane and fluid allografts (including AmnioFix) are used in orthopedic, spine, and wound care procedures — anti-inflammatory properties, tissue processing standards, and published outcomes data.
-
COMPARISON
PRP vs Stem Cell vs Amniotic Tissue: Comparing Regenerative Options
A side-by-side comparison of the three primary regenerative modalities — mechanism of action, FDA regulatory status, clinical indications, cost per application, and strength of evidence for each.
Access Biologics Through SLR Medical
SLR Medical Consulting supplies amniotic tissue products, AmnioFix, and sports medicine biologics to surgical facilities and ASCs nationwide. Contact us for product availability, pricing, and clinical support.
Explore More Resources
Frequently Asked Questions
Are biologics FDA-approved for orthopedic use?
It depends on the product category. Bone morphogenetic proteins (like Infuse/BMP-2) are FDA-approved devices with specific labeled indications. PRP systems are FDA-cleared as blood processing devices, but PRP itself is not FDA-approved for specific orthopedic indications — it’s used at the surgeon’s clinical discretion. Amniotic tissue products are regulated as human cells, tissues, and cellular/tissue-based products (HCT/Ps) under Section 361 of the Public Health Service Act, meaning they don’t require FDA premarket approval if they meet certain processing criteria. The regulatory status affects reimbursement, marketing claims, and clinical liability.
What is the difference between amniotic tissue and stem cell therapy?
Amniotic tissue allografts are processed from donated placental tissue after scheduled C-sections. They contain growth factors, cytokines, and extracellular matrix proteins that modulate inflammation and support tissue repair — but minimally processed amniotic products do not contain viable, functional stem cells despite marketing claims to the contrary. Stem cell therapy typically refers to bone marrow aspirate concentrate (BMAC) or adipose-derived stromal cells harvested from the patient during the procedure. The distinction matters clinically and regulatorily: amniotic products are off-the-shelf; BMAC requires same-day harvest from the patient’s iliac crest.
How much do biologics cost per surgical case?
Costs vary widely. PRP preparation from a bedside centrifuge system runs $200-$600 per case. Amniotic tissue allografts typically cost $500-$3,000 depending on size and processing method. DBM (demineralized bone matrix) for spine fusion runs $800-$2,500 per application. BMP-2 (Infuse) can cost $3,000-$5,000 per kit. BMAC harvest and processing adds $1,500-$3,000. Reimbursement coverage varies by payer, clinical indication, and care setting (hospital outpatient vs. ASC), which significantly affects the facility’s decision to stock and use specific biologics products.